Nephrology Dialysis Transplantation最新文献

{"title":"Obinutuzumab for the management of immune-mediated glomerular diseases.","authors":"Giovanni M Rossi, Eva Baier, Augusto Vaglio","doi":"10.1093/ndt/gfaf021","DOIUrl":"10.1093/ndt/gfaf021","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1443-1448"},"PeriodicalIF":5.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"More versus less intensive blood pressure reduction and kidney function outcomes-Waiting for Godot?","authors":"Raymond R Townsend","doi":"10.1093/ndt/gfaf034","DOIUrl":"10.1093/ndt/gfaf034","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1452-1454"},"PeriodicalIF":5.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and characteristics of chronic kidney disease in the Hamburg City Health Study.","authors":"Christian Schmidt-Lauber, Christina Thompson, Elisa Alba Schmidt, Alexandre Klopp, Ammar Alabdo, Tanja Zeller, Ines Schäfer, Raphael Twerenbold, Christoffer Johansen, Stefan Blankenberg, Tobias B Huber","doi":"10.1093/ndt/gfaf075","DOIUrl":"10.1093/ndt/gfaf075","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1632-1634"},"PeriodicalIF":5.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12315801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exon location of glycine substitutions impacts kidney survival in autosomal dominant Alport syndrome.","authors":"Marie-Sophie Pagniez, Victor Fages, Clémence Gatinois, Romain Larrue, Nicolas Pottier, Timothée Laboux, Rémi Lenain, Olivier Grunewald, Thomas Robert, Claire Rigothier, Laurent Mesnard, François Glowacki","doi":"10.1093/ndt/gfaf011","DOIUrl":"10.1093/ndt/gfaf011","url":null,"abstract":"<p><strong>Background: </strong>Unlike X-linked or autosomal recessive Alport syndrome, no clear genotype/phenotype correlation has yet been demonstrated in patients carrying a single variant of COL4A3 or COL4A4.</p><p><strong>Methods: </strong>We carried out a multicentre retrospective study to assess the risk factors involved in renal survival in patients presenting a single pathogenic variant on COL4A3 or COL4A4.</p><p><strong>Results: </strong>A total of 97 patients presenting a single pathogenic variant of COL4A3 or COL4A4 were included. The prevalence of end-stage kidney disease (ESKD) during follow-up was 28.7% [median age 47.5 years (interquartile range 39.1-55.8). A total of 23 patients carried a 'severe' mutation (frameshift, stop gain, extensive deletion, impacting splicing) and 60 patients presented a glycine substitution in a collagenous domain. In patients with glycine missense variants, the location of the mutation in the distal exons was associated with worse renal survival with a more pronounced decline in the estimated glomerular filtration rate compared with variants in proximal exons. Conversely, the presence of a severe mutation did not impact renal survival.</p><p><strong>Conclusion: </strong>Our results confirm that autosomal dominant Alport syndrome (ADAS) can lead to ESKD. We demonstrated that a glycine substitution involving the distal exons had a negative impact on renal survival in ADAS patients, probably due to a trimerization defect. This could help improve personalized follow-up in ADAS patients with glycine substitution and could be integrated into a future prognostic score to accurately predict renal outcomes.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1522-1530"},"PeriodicalIF":5.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of haemodiafiltration versus haemodialysis on vascular access patency when starting haemodialysis.","authors":"Mahoko Yoshida, Yujiro Maeoka, Akira Takahashi, Naoki Ishiuchi, Yosuke Osaki, Kensuke Sasaki, Takao Masaki","doi":"10.1093/ndt/gfaf017","DOIUrl":"10.1093/ndt/gfaf017","url":null,"abstract":"<p><strong>Background: </strong>Haemodiafiltration (HDF) therapy improves the prognosis by reducing inflammation and oxidative stress and improving endothelial function. These factors contribute to vascular access (VA) stenosis, one of the most common complications in patients on haemodialysis (HD) or HDF. This study aimed to assess the efficacy of HDF on VA patency.</p><p><strong>Methods: </strong>This multicentre, prospective, observational study with post hoc analysis included 612 patients among 643 who underwent VA procedures and started dialysis between April 2012 and March 2021. A total of 516 patients were on HD since starting dialysis, while 96 switched to HDF after starting dialysis. One-to-one propensity score matching was performed to compare the 24-month patency rates of VA between groups by Kaplan-Meier and logrank tests, and a Cox proportional hazards regression analysis was used to identify factors affecting patency rates.</p><p><strong>Results: </strong>There were 87 patients in each group. The 24-month primary patency rates were 74.2% for HDF and 47.7% for HD (P < .001). A multivariate Cox proportional hazards analysis showed that a history of cardiovascular disease {hazard ratio [HR] 2.29 [95% confidence interval (CI) 1.21-4.34], P = .01} and higher haemoglobin A1c values [HR 1.37 (95% CI 1.00-1.82), P = .04] were associated with poor 24-month primary patency. However, HDF [HR 0.30 (95% CI 0.16-0.56), P < .001] and use of statins [HR 0.50 (95% CI 0.27-0.94), P = .03] were associated with better patency. A stratified analysis showed that HRs for loss of VA patency were lower in patients with HDF than in those with HD in the subgroups of ≥65 years, male sex, radiocephalic arteriovenous fistula, a history of diabetes mellitus or cardiovascular disease, haemoglobin concentrations <10 g/dl and albumin concentrations <3.5 g/dl.</p><p><strong>Conclusions: </strong>HDF potentially improves VA patency rates compared with HD, even in patients with cardiovascular disease or diabetes, commonly associated with poor patency.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1538-1549"},"PeriodicalIF":5.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143040518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Music-based interventions in mild cognitive impairment and kidney disease: a scoping review on behalf of CONNECT (Cognitive decline in Nephro-Neurology European Cooperative Target) action.","authors":"Filippo Giordano, Stefania Rotella, Giovambattista Capasso, Marco Fiorentino, Loreto Gesualdo","doi":"10.1093/ndt/gfaf041","DOIUrl":"10.1093/ndt/gfaf041","url":null,"abstract":"<p><p>Music-based interventions (MBIs) have shown promise in enhancing cognitive and behavioural functions in patients with mild cognitive impairment (MCI). This review aims to synthesize current knowledge on the clinical application of MBIs in MCI and explore their potential use in patients with chronic kidney disease (CKD). A systematic search was conducted in the PubMed, PsycInfo, Cochrane Library and Scopus databases for studies published between January 2013 and October 2023. The search focused on MBIs applied to MCI and CKD patients. We collected data on study design, type of MBIs administered and main clinical outcomes. Sixteen studies were included in this review, ten of which were randomized controlled trials. MBIs ranged from passive music listening (four studies) to active participation in music-making (vocal or singing activities, playing instruments and improvisation, music interventions associated with physical activity, musical stimulation). While no studies specifically focused on CKD patients, cognitive improvements were generally more significant with active interventions, whereas behavioural benefits were more associated with receptive approaches. MBIs showed potential benefits in improving cognitive and depressive symptoms associated with MCI. Given the high prevalence of MCI in CKD patients, future studies should investigate the application of MBIs in this population.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1483-1497"},"PeriodicalIF":5.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IdeZ protease does not prevent convertase stabilization by C3 nephritic factors in C3 glomerulopathy.","authors":"Kes H Stevens, Laura M Baas, Nicole C A J van de Kar, Lambertus P W J van den Heuvel, Marloes A H M Michels","doi":"10.1093/ndt/gfaf065","DOIUrl":"10.1093/ndt/gfaf065","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1628-1631"},"PeriodicalIF":5.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12315799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidney aging and chronic kidney disease-another perspective.","authors":"Richard J Glassock, Andrew D Rule, Aleksandar Denic, Pierre Delanaye","doi":"10.1093/ndt/gfaf087","DOIUrl":"10.1093/ndt/gfaf087","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1455-1457"},"PeriodicalIF":5.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of acute kidney injury in relapsed and refractory multiple myeloma treated with teclistamab versus CAR-T cells.","authors":"Mariam Charkviani, Maria Jose Vargas Brochero, Arjunmohan Mohan, Lisa E Vaughan, Tyler B Sandahl, Andre De Menezes Silva Corraes, Yi Lin, Nelson Leung, Sandra M Herrmann","doi":"10.1093/ndt/gfaf004","DOIUrl":"10.1093/ndt/gfaf004","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>Teclistamab, a novel bispecific monoclonal antibody targeting CD3 and B cell maturation antigen (BCMA), and chimeric antigen receptor T cell (CAR-T) therapy are promising options for treating relapsed/refractory multiple myeloma (MM). However, the rates of acute kidney injury (AKI) associated with teclistamab remain inadequately characterized. This study aims to compare the incidence, severity, and outcomes of AKI between patients receiving teclistamab and CAR-T therapy.</p><p><strong>Methods: </strong>This was a retrospective study involving 64 patients with relapsed/refractory MM treated with either teclistamab or CAR-T therapy. All patients had previously received at least four lines of chemotherapy before being treated with either teclistamab or CAR-T. The primary outcome was the incidence of AKI, and secondary outcomes included AKI severity, kidney recovery rates, and mortality. Kaplan-Meier estimates for AKI-free survival were calculated, and hazard ratios (HRs) for AKI risk were determined using Cox proportional hazards models.</p><p><strong>Results: </strong>Sixty-four patients met inclusion criteria for this study (30 received CAR-T and 34 received teclistamab therapy). Among these patients, 14 AKI events occurred in total (22%), with 10 events (29%) in the teclistamab group and four events (13%) in the CAR-T group. AKI-free survival estimates at 180 days after treatment initiation were 68% [95% confidence interval (CI): 53%-87%] for teclistamab patients and 90% (95% CI: 79%-100%) for CAR-T patients. While patients receiving teclistamab were found to have an increased risk of an AKI event compared to those receiving CAR-T therapy, the results were not statistically significant [HR (95% CI): 3.38 (0.93-12.31), P = .065].</p><p><strong>Conclusions: </strong>This study suggests that patients treated with teclistamab may experience a higher incidence of AKI compared to those receiving CAR-T therapy. However, further research is required to determine whether this increased risk is attributable to disease progression or teclistamab itself. These results highlight the need for close kidney function monitoring in patients receiving teclistamab.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1512-1521"},"PeriodicalIF":5.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The autonomic nervous system and inflammation in chronic kidney disease.","authors":"Carmine Zoccali, Francesca Mallamaci, Mehmet Kanbay, Katherine R Tuttle, Peter Kotanko, Raffaele De Caterina, Guido Grassi, Giuseppe Mancia","doi":"10.1093/ndt/gfaf020","DOIUrl":"10.1093/ndt/gfaf020","url":null,"abstract":"<p><p>The autonomic nervous system plays a crucial role in regulating physiological processes and maintaining homeostasis through its two branches: the sympathetic nervous system and the parasympathetic nervous system. Dysregulation of the autonomic system, characterized by increased sympathetic activity and reduced parasympathetic tone, is a common feature in chronic kidney disease (CKD) and cardiovascular disease. This imbalance contributes to a pro-inflammatory state, exacerbating disease progression and increasing the risk for cardiovascular events. The sympathetic system promotes inflammation by releasing catecholamines, which activate adrenergic receptors on immune cells. The parasympathetic system exerts anti-inflammatory effects via the cholinergic anti-inflammatory pathway mediated by the vagus nerve. Targeting the autonomic system to restore the balance between the sympathetic and the parasympathetic components offers promising approaches to reduce inflammation and improve outcomes in CKD and cardiovascular disease. β-Blockers, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers are pharmacological agents that modulate sympathetic activity and have shown anti-inflammatory effects. Lifestyle interventions, such as a healthy diet, physical exercise, mindfulness, and meditation, enhance parasympathetic activity and improve autonomic function. Vagus nerve stimulation has emerged as a promising therapy, demonstrating significant potential in reducing inflammation and improving clinical outcomes in various conditions, including CKD, myocardial infarction, and stroke. Despite mixed results in heart failure trials, vagal nerve stimulation has consistently improved quality-of-life measures. Understanding the mechanisms underlying autonomic system regulation of inflammation can inform the development of novel therapeutic strategies to restore autonomic balance and improve patient outcomes in CKD and cardiovascular disease.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1470-1482"},"PeriodicalIF":5.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}